Investigating new biomarkers to use EGFR inhibitors for colorectal cancer patients with mutant KRAS.
Exploration of Novel Mutation Biomarkers to Repurpose EGFRi for Mutant KRAS Colorectal Cancer
This study is looking at whether a specific cancer treatment called cetuximab can help patients with metastatic colorectal cancer who have a certain gene mutation (mutant KRAS) that usually makes them less likely to benefit from this type of therapy, giving hope for a new option for those who haven't had many choices before.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10449283 on NIH RePORTER |
What this research studies
This research explores the potential of using epidermal growth factor receptor inhibitors (EGFRi) in patients with metastatic colorectal cancer (CRC) who have mutant KRAS. Traditionally, these patients have been considered non-responsive to EGFRi, but recent findings suggest that certain genetic mutations may indicate sensitivity to these treatments. The study aims to validate these biomarkers through a clinical trial, offering a new therapeutic option for patients who have been historically overlooked. Patients will be monitored for their response to cetuximab, an EGFRi, in a controlled setting.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic colorectal cancer who have been diagnosed with mutant KRAS and may have specific genetic mutations like APC and TP53.
Not a fit: Patients with colorectal cancer who do not have mutant KRAS or those who have other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for colorectal cancer patients with mutant KRAS, potentially improving their prognosis.
How similar studies have performed: While the approach of repurposing EGFR inhibitors for mutant KRAS patients is novel, preliminary findings suggest potential success in similar investigations.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Florou, Vaia — University of Utah
- Study coordinator: Florou, Vaia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.